Hot Features
프리미엄
Mgi Pharma (MM) (MOGN)
NASDAQ
같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the successful completion of its acquisition of MGI PHARMA, INC...
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the completion of the offer by its indirect wholly-owned...
NEW YORK, Jan. 23 /PRNewswire/ -- QED International Associates, Inc., administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded...
Eisai Co., Ltd. (Tokyo, TSE 4523) (?Eisai?), a research-based human health care (hhc) company, today announced the satisfaction of all of the conditions to the offer by its...
MGI PHARMA, INC. (NASDAQ:MOGN), a biopharmaceutical company focused in oncology and acute care, today announced that study results published in the February issue of the Journal...
Eisai Co., Ltd. (Tokyo, TSE: 4523) (?Eisai?) and MGI PHARMA, INC. (NASDAQ: MOGN) (?MGI PHARMA?) announced today that the Federal Trade Commission has granted early termination...
NEW YORK, Jan. 16 /PRNewswire/ -- HMS Holdings Corp. (NASDAQ:HMSY) will replace MGI PHARMA Inc. (NASDAQ:MOGN) in the S&P SmallCap 600 after the close of trading on Tuesday, January 22. MOGN is...
On December 26, 2007, MGI PHARMA, INC. issued a Notice of Conversion Right to holders of its Senior Subordinated Convertible Notes due 2024. The notice incorrectly listed...
MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, and its partner HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical...
MGI PHARMA, INC. (NASDAQ:MOGN) (the ?Company? or ?MGI PHARMA?), today announced that the Company?s Senior Subordinated Convertible Notes due 2024 (the ?Notes?) shall become...
| 기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
